NEW YORK, June 20 - Oxford Glycosciences and NeoGenesis have agreed to partner in an effort to identify small molecule drugs for OGS' protein targets, the companies said Wednesday. 

OGS, of Oxford, UK, will provide an undisclosed number of protein targets to NeoGenesis, and pay NeoGenesis research fees, milestone payments, and royalties for lead compounds that the company identifies. OGS will commercialize any lead compounds, and is also making an undisclosed equity investment in NeoGenesis.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.